Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 14/20 | 0.47 |
| ▸ | ESR1 | P03372 | 13/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | MRGPRX1 | Q96LB2 | 1/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL537679 | 0.93 | OGA (0.40) | ESR2ESR1ADORA2AADORA3ADORA2B | |
| SCHEMBL538613 | 0.85 | POLB (0.38) | ADORA2AADORA1 | |
| SCHEMBL2814652 | 0.80 | MEN1 (0.48) | — | |
| SCHEMBL2809671 | 0.79 | OGA (0.40) | — | |
| SCHEMBL2810531 | 0.78 | MRGPRX1 (0.48) | ESR2ESR1MRGPRX1 | |
| SCHEMBL2816668 | 0.77 | MRGPRX1 (0.39) | ESR2ESR1MRGPRX1 | |
| SCHEMBL2813871 | 0.77 | MRGPRX1 (0.39) | ESR2ESR1MRGPRX1 | |
| SCHEMBL2810595 | 0.76 | NPY5R (0.37) | ADORA2AADORA3 | |
| SCHEMBL2810273 | 0.75 | ADORA3 (0.41) | ADORA2AADORA3ADORA1MRGPRX1 | |
| SCHEMBL2812918 | 0.73 | MRGPRX1 (0.38) | MRGPRX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8343983-B2 | Substituted pyrazolo-pyrimidine compounds | ARQULE, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-20100249110-A1 | SUBSTITUTED PYRAZOLO-PYRIMIDINE COMPOUNDS | ARQULE, INC. (US) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249110-A1 | SUBSTITUTED PYRAZOLO-PYRIMIDINE COMPOUNDS | DPYD, TYMP, TP53 | ESR2 3400/4885ESR1 3470/4885ADORA2A 470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.